SCHEMBL8136707

SCHEMBL8136707

CCc1nc(Cl)c(Cc2ccccc2C)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.39
DDAH1 O94760 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
TP53 P04637 1/20 0.36
KDR P35968 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
AR P10275 1/20 0.35
P2RX7 Q99572 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3028010 0.69 TSHR (0.44) DDAH1L3MBTL1ALDH1A1TP53TNKS2
SCHEMBL3027998 0.68 GAA (0.39) DDAH1MEN1GAAKMT2A
SCHEMBL11298020 0.66 EGFR (0.47) EGFRL3MBTL1ALDH1A1MEN1GAA
SCHEMBL29477327 0.65 TAAR1 (0.56) ALDH1A1KMT2AARP2RX7HPGD
SCHEMBL2090458 0.65 TAAR1 (0.56) ALDH1A1KMT2AARP2RX7HPGD
SCHEMBL25047048 0.65 L3MBTL1 (0.44) DDAH1L3MBTL1ALDH1A1GAATP53
SCHEMBL11210876 0.65 TAAR1 (0.46) ALDH1A1KMT2AARHPGD
SCHEMBL6548002 0.65 TAAR1 (0.46) ALDH1A1KMT2AARHPGD
SCHEMBL4119398 0.64 EGFR (0.74) EGFRDDAH1L3MBTL1ALDH1A1MEN1
SCHEMBL11200954 0.63 TAAR1 (0.54) ALDH1A1KMT2AARP2RX7HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994877-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Du Pont Pharmaceuticals Company (US) 2000-04-26 EP disclosed
WO-1999001454-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DU PONT PHARMACEUTICALS COMPANY (US) 1999-01-14 WO disclosed